Table 3.
Grade 3 or 4 toxicity (adverse events considered at least possibly related to tipifarnib) was observed in 58% (54 of 93) of patients
| Toxicity | Grade 3 | Grade 4 | Total, no. (%) |
|---|---|---|---|
| General | |||
| Fatigue | 9 | 0 | 9 (10) |
| Hypotension | 0 | 1 | 1 (1) |
| Prolonged PT | 1 | 0 | 1 (1) |
| Dehydration | 2 | 0 | 2 (2) |
| Hematologic | |||
| Anemia | 8 | 2 | 10 (11) |
| Neutropenia | 7 | 27 | 34 (37) |
| Thrombocytopenia | 13 | 17 | 30 (32) |
| Infection | |||
| Febrile neutropenia | 2 | 2 | 4 (4) |
| Bacteremia | 1 | 1 | 2 (2) |
| Pneumonia | 1 | 0 | 1 (1) |
| Respiratory tract | 0 | 1 | 1 (1) |
| Wound/soft tissue | 2 | 0 | 2 (2) |
| Sinus | 1 | 0 | 1 (1) |
| Metabolic | |||
| Hypokalemia | 1 | 0 | 1 (1) |
| Gastrointestinal | |||
| Diarrhea | 1 | 0 | 1 (1) |
| Pulmonary | |||
| Dyspnea | 1 | 0 | 1 (1) |
| Pneumonitis | 1 | 0 | 1 (1) |
Thirty-six patients (39%) experienced at least one grade 4 toxicity. Regarding nonhematologic toxicity, 18 patients (19%) had at least one grade 3 toxicity, and 3 patients (3%) had one grade 4 toxicity. PT indicates prothrombin time.